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AbstrACt
Objective Within the last years, there has been 
growing awareness of the negative repercussions of 
unstandardized planning, conduct and reporting of 
preclinical and biomedical research. Several initiatives 
have set the aim of increasing validity and reliability in 
reporting of studies and publications, and publishers have 
formed similar groups. Additionally, several groups of 
experts across the biomedical spectrum have published 
experience and opinion-based guidelines and guidance on 
potential standardized reporting. While all these guidelines 
cover reporting of experiments, an important step prior 
to this should be rigours planning and conduction of 
studies. The aim of this systematic review is to identify 
and harmonize existing experimental design, conduct 
and analysis guidelines relating to internal validity 
and reproducibility of preclinical animal research. The 
review will also identify literature describing risks of 
bias pertaining to the design, conduct and analysis of 
preclinical biomedical research. 
search strategy PubMed, Embase and Web of Science 
will be searched systematically to identify guidelines 
published in English language in peer-reviewed journals 
before January 2018 (box 1). All articles or systematic 
reviews in English language that describe or review 
guidelines on the internal validity and reproducibility 
of animal studies will be included. Google search for 
guidelines published on the websites of major funders and 
professional organisations can be found in (Box 2). 
screening and annotation Unique references will be 
screened in two phases: screening for eligibility based 
on title and abstract, followed by screening for definitive 
inclusion based on full text. Screening will be performed in 
SyRF (http:// syrf. org. uk). Each reference will be randomly 
presented to two independent reviewers. Disagreements 
between reviewers will be resolved by additional screening 
of the reference by a third, senior researcher. 
Data management and reporting All data, including 
extracted text and guidelines, will be stored in the 
SyRF platform. Elements of the included guidelines 
will be identified using a standardized extraction form. 
Reporting will follow the PRISMA guidelines as far as 
applicable. 
IntrODuCtIOn
Within the  last years, there has been growing 
awareness of the negative repercussions 
of unstandardised planning, conduct and 
reporting of preclinical and biomedical 
research.1 2 Several initiatives have set the 
aim of increasing validity and reliability in 
reporting of (not only preclinical) studies and 
publications, such as CAMARADES (Collabo-
rative Approach to Meta-Analysis and Review 
of Animal Data from Experimental Studies),3 
NC3Rs (The National Centre for the 3Rs),4 
SYRCLE (SYstematic Review Center for Labo-
ratory animal Experimentation)5 and the 
EQUATOR (Enhancing the QUAlity and 
Transparency Of health Research) network.6 
Publishers have formed similar groups (eg, The 
Lancet’s REWARD (REduce research Waste And 
Reward Diligence) initiative7). Additionally, 
several experts or groups of experts across the 
biomedical spectrum, both clinical and preclin-
ical, have published experience and opinion 
based guidelines and guidance on potential 
standardised reporting.8–10 While many of the 
points raised are identical or similar between 
these various guidelines (in fact many experts 
on the field are part of more than one initia-
tive), they differ in details, rigour and show 
especially distinct variance in generalisability 
or specific challenges for a single field. While 
all these guidelines cover reporting of experi-
ments, an important step prior to this should 
be rigours planning and conduction of studies, 
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it is hard for researchers to decide which guidelines to 
follow, especially at the stage of planning future studies.   
The aim of this systematic review is to identify and 
harmonise existing experimental design, conduct and 
analysis guidelines relating to preclinical animal research. 
The review will also identify literature describing (either 
through primary research or systematic review) risks of bias 
pertaining to the design, conduct and analysis of preclinical 
biomedical research. Reporting standards will be consid-
ered if they refer to topics that are important to consider 
at planning or experimental, not only at reporting, stage. 
This review will focus on internal validity and reproduc-
ibility of experimental design, conduct and analysis. While 
we realise that factors like animal housing and welfare are 
box 1 Continued
consensus development/ or practice guideline/ or position statement*.
ti,ab,kw. OR policy statement*.ti,ab,kw. OR practice parameter*.
ti,ab,kw. or best practice*.ti,ab,kw. OR standards.ti. OR guideline.
ti. OR guidelines.ti. OR recommendation.ti. OR recommendations.ti.) 
AND ((Preclinical.ti,ab,kw. OR Pre-clinical.ti,ab,kw. OR Experimental.
ti,ab,kw. OR animal.ti,ab,kw.) adj2 (Study.ti,ab,kw. OR Studies.
ti,ab,kw. OR Model.ti,ab,kw. OR Models.ti,ab,kw.)) AND animal.mp.) 
OR ((methodology/ or experimental design/ or study design/) and (tool.
ti. or protocol.ti.) and (exp animal experiment/ or exp animal model/ 
or ((Preclinical.ti,ab,kw. OR Pre-clinical.ti,ab,kw. OR Experimental.
ti,ab,kw. OR animal.ti,ab,kw.) adj2 (Study.ti,ab,kw. OR Studies.ti,ab,kw. 
OR Model.ti,ab,kw. OR Models.ti,ab,kw.))) AND animal.mp.) 
box 1 search string
Web of Science 
(guideline OR recommendation OR recommendations) AND 
(“preclinical model” OR “preclinical models” OR “disease model” 
OR “disease models” OR “animal model” OR “animal models” OR 
“experimental model” OR “experimental models” OR “preclinical 
study” OR “preclinical studies” OR “animal study” OR “animal studies” 
OR “experimental study” OR “experimental studies”) 
PubMed 
((Consensus[mh] OR Consensus development conferences as 
topic[mh] OR Guidelines as topic [Mesh] OR Practice guidelines as 
topic[mh] OR guideline[pt] OR practice guideline[pt] OR consensus 
development conference[pt] OR position statement*[tiab] OR 
policy statement*[tiab] OR practice parameter*[tiab] OR best 
practice*[tiab] OR standards[ti] OR guideline[ti] OR guidelines[ti] 
OR recommendation[ti] OR recommendations[ti]) AND (“Animal 
Experimentation”[Mesh] OR “Models, Animal”[Mesh] OR Preclinical 
model[tiab] OR Pre-clinical model[tiab] OR Preclinical models[tiab] 
OR Pre-clinical models[tiab] OR disease model[tiab] OR disease 
models[tiab] OR animal model[tiab] OR animal models[tiab] 
OR experimental model[tiab] OR experimental models[tiab] OR 
preclinical study[tiab] OR pre-clinical study[tiab] OR preclinical 
studies[tiab] OR pre-clinical studies[tiab] OR animal study[tiab] OR 
animal studies[tiab] OR animal experiment*[tiab] OR experimental 
study[tiab] OR experimental studies[tiab])) OR ((Consensus[mh] OR 
Consensus development conferences as topic[mh] OR Guidelines as 
topic [Mesh] OR Practice guidelines as topic[mh] OR guideline[pt] 
OR practice guideline[pt] OR consensus development conference[pt] 
OR position statement*[tiab] OR policy statement*[tiab] OR 
practice parameter*[tiab] OR best practice*[tiab] OR standards[ti] 
OR guideline[ti] OR guidelines[ti] OR recommendation[ti] OR 
recommendations[ti]) AND ((Preclinical[tiab] OR Pre-clinical[tiab] OR 
Experimental[tiab] OR animal[tiab]) AND (Study[tiab] OR Studies[tiab] 
OR Model[tiab] OR Models[tiab]) AND animals[Mesh:noexp])) OR 
(((“Methods”[Mesh] OR “methods”[Subheading]) AND (tool[ti] OR 
protocol[ti])) AND (“Animal Experimentation”[Mesh] OR “Models, 
Animal”[Mesh] OR ((Preclinical[tiab] OR Pre-clinical[tiab] OR 
Experimental[tiab] OR animal[tiab]) AND (Study[tiab] OR Studies[tiab] 
OR Model[tiab] OR Models[tiab])) AND animals[Mesh:noexp])) 
OR ((position statement*[tiab] OR policy statement*[tiab] OR 
practice parameter*[tiab] OR best practice*[tiab] OR standards[ti] 
OR guideline[ti] OR guidelines[ti] OR recommendation[ti] OR 
recommendations[ti]) AND ((Preclinical[tiab] OR Pre-clinical[tiab] OR 
Experimental[tiab] OR animal[tiab]) AND (Study[tiab] OR Studies[tiab] 
OR Model[tiab] OR Models[tiab])) NOT medline[sb])
Embase
(Consensus/ or consensus development/ or practice guideline/ or 
position statement*.ti,ab,kw. OR policy statement*.ti,ab,kw. OR 
practice parameter*.ti,ab,kw. or best practice*.ti,ab,kw. OR standards.
ti. OR guideline.ti. OR guidelines.ti. OR recommendation.ti. OR 
recommendations.ti.) AND (exp animal experiment/ or exp animal 
model/ or Preclinical model.ti,ab,kw. OR Pre-clinical model.ti,ab,kw. 
OR Preclinical models.ti,ab,kw. OR Pre-clinical models.ti,ab,kw. OR 
disease model.ti,ab,kw. OR disease models.ti,ab,kw. OR animal 
model.ti,ab,kw. OR animal models.ti,ab,kw. OR experimental model.
ti,ab,kw. OR experimental models.ti,ab,kw. OR preclinical study.
ti,ab,kw. OR pre-clinical study.ti,ab,kw. OR preclinical studies.ti,ab,kw. 
OR pre-clinical studies.ti,ab,kw. OR animal study.ti,ab,kw. OR animal 
studies.ti,ab,kw. OR animal experiment*.ti,ab,kw. OR experimental 
study.ti,ab,kw. OR experimental studies.ti,ab,kw.) OR ((Consensus/ or 
Continued
box 2 List of funders and organisations
Professional neuroscientific organisations
Society for Neuroscience (USA)
Cognitive Neuroscience Society (USA)
American College for Neuropsychopharmacology (USA)
Federation of European Neuroscience Societies (EU)
European Brain and Behaviour Society (EU)
European College of Neuropsychopharmacology (EU)
British Neuroscience Association (UK) 
Major funders
National Institute of Health & Howard Hughes Medical Institute (USA) 
Chinese Academy of Sciences & National Natural Sciences Foundation 
of China (China) 
Japan Society for the Promotion of Science & Japan Neuroscience 
Society (Japan) 
European Research Council & Horizon 2020 & Innovative Medicines 
Initiative (EU) 
Wellcome Trust & Medical Research Council (UK) 
Deutsche Forschungsgemeinschaft (Germany) 
L'agence Nationale de la Recherche & Pasteur Foundation (France) 
Dirección General de Investigación Científica y Técnica & Instituto de  
Salud Carlos III (Spain) 
Ministry of Instruction, Universities, and Research (Italy) 
Ministry of Education and Science, Russian Science Foundation and 
Russian Foundation for Fundamental Research (Russia) 
Ministry of Science and Higher Education (Poland) 
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highly important for reproducibility of experiments, they 
will not be considered in this initial systematic review (SR), 
which focuses on internal validity. It is planned to analyse 
the influence of animal care and use at a later point in a 
separate SR.
InCLusIOn AnD exCLusIOn CrIterIA
This study will include all articles or systematic reviews in 
English language that describe or review guidelines on the 
internal validity (‘to what extent do the study results reflect 
a true cause–effect of the intervention?’) and reproduc-
ibility of the design, conduct and analysis of preclinical 
animal studies. Articles that focus strictly focus on toxicity 
or veterinary drugs only will not be included. Litera-
ture not focussing on guidelines, but describing (either 
through primary research or systematic review) risks of bias 
pertaining to the design, conduct and analysis of preclin-
ical biomedical research, will also be considered. Although 
reporting standards are not the key primary objective of 
this systematic review these will also be searched, screened 
and extracted, as they can contain useful information that 
should be considered not only at reporting, but already at 
planning or experimental stage.
sCreenIng AnD AnnOtAtIOn
After combining the search results from all sources, poten-
tial duplicates or publication of identical guidelines by the 
same author group in various journals will be identified prior 
to screening, based on PubMed ID, digital object identifier 
(DOI) and title, journal and author list. Unique references 
will then be screened in two phases: (1) screening for eligi-
bility based on title and abstract, followed by (2) screening 
for definitive inclusion based on full text. Screening will be 
performed in SyRF (http:// syrf. org. uk). Each reference 
will be randomly presented to two independent reviewers. 
Reviewers are not blinded to the authors of the presented 
record. In the first stage, two authors will screen the title 
and abstract of the retrieved records for eligibility based on 
predefined inclusion criteria (see above). The title/abstract 
screening stage will focus on sensitivity (‘could the paper be 
of any interest?’).
Articles included after the title-abstract screening will 
undergo concurrent full-text screening for definitive 
inclusion. We will attempt to obtain full-text versions of 
all included articles through open access, interlibrary 
loan or by contacting authors directly. Articles for which 
no full-text version can be obtained will be excluded 
from the review.
In both screening stages, disagreements between 
reviewers will be resolved by additional screening of the 
reference by a third, senior researcher, who is blind to the 
individual judgements of the first two reviewers.
DAtA mAnAgement
All references returned from the searches will be down-
loaded, with entries organised by DOI (if available, or 
weblink alternatively), publication date, and title. All data, 
box 3 extraction form
1. Matching or balancing treatment allocation of animals. 
2. Matching or balancing sex of animals across groups. 
3. Standardised handling of animals. 
4. Randomised allocation of animals to treatment. 
5. Randomisation for analysis. 
6. Randomised distribution of animals in the animal facilities. 
7. Monitoring emergence of confounding characteristics in animals. 
8. Specification of unit of analysis. 
9. Addressing confounds associated with anaesthesia or analgesia. 
10. Selection of appropriate control groups. 
11. Concealed allocation of treatment. 
12. Study of dose–response relationships. 
13. Use of multiple time points measuring outcomes. 
14. Consistency of outcome measurement. 
15. Blinding of outcome assessment. 
16. Establishment of primary and secondary end points. 
17. Precision of effect size. 
18. Management of conflicts of interest. 
19. Choice of statistical methods for inferential analysis. 
20. Recording of the flow of animals through the experiment. 
21. A priori statements of hypothesis. 
22. Choice of sample size. 
23. Addressing confounds associated with treatment. 
24. Characterisation of animal properties at baseline. 
25. Optimisation of complex treatment parameters. 
26. Faithful delivery of intended treatment. 
27. Degree of characterisation and validity of outcome. 
28. Treatment response along mechanistic pathway. 
29. Assessment of multiple manifestations of disease phenotype. 
30. Assessment of outcome at late/relevant time points. 
31. Addressing treatment interactions with clinically relevant 
comorbidities. 
32. Use of validated assay for molecular pathways assessment. 
33. Definition of outcome measurement criteria. 
34. Comparability of control group characteristics to those of previous 
studies. 
35. Reporting on breeding scheme. 
36. Reporting on genetic background. 
37. Replication in different models of the same disease. 
38. Replication in different species or strains. 
39. Replication at different ages. 
40. Replication at different levels of disease severity. 
41. Replication using variations in treatment. 
42. Independent replication. 
43. Addressing confounds associated with experimental setting. 
44. Addressing confounds associated with setting. 
45. Preregistration of study protocol and analysis procedures. 
46. Pharmacokinetics to support treatment decisions. 
47. Definition of treatment. 
48. Interstudy standardisation of end point choice. 
49. Define programmatic purpose of research. 
50. Interstudy standardisation of experimental design. 
51. Research within multicentre consortia. 
52. Critical appraisal of literature or systematic review during design 
phrase. 
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including extracted text and guidelines, will be stored in 
the SyRF platform.
stuDy quALIty, metA-AnALysIs AnD rIsk Of bIAs 
Assessment
These typical stages of systematic reviews are not relevant 
for this study, as it focusses on guidelines rather than exper-
imental data.
However, both reviewers will rate extracted guidelines 
rated based on the following system (Ia being the lowest 
level of provenance, IIIb being the highest):
I. Recommendations of individuals or small groups of 
individuals based on individual experience only
a. Published stand alone.
b. Endorsed or initiated by at least one publisher or 
scientific society.
II. Recommendations by groups of individuals, includ-
ing a Delphi process
a. Published stand alone.
b. Endorsed or initiated by at least one publisher or 
scientific society.
III. Recommendations based on a systematic review
a. Published stand alone.
b. Endorsed or initiated by at least one publisher or 
scientific society.
Across guidelines, the elements will be ranked based on 
the frequency of appearance across the included guidelines.
repOrtIng
Elements of the included guidelines will be identified using 
the extraction form from box 3. Additionally, reporting will 
follow the Preferred Reporting Items for Systematic Review 
and Meta-analysis guidelines as far as applicable.
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